Why Oscar Health is on investors’ radar now

Oscar Health (OSCR) has attracted attention after a period of weak share performance, with negative returns over the past month, past 3 months, year to date, and past year prompting closer scrutiny from investors.

The recent slide in Oscar Health’s share price, including a 1 day share price return of a 1.20% decline and a 30 day share price return of a 21.56% decline, has cooled short term momentum, even though the 3 year total shareholder return of about 122% still reflects a very strong longer term move.

If this pullback has you looking beyond a single stock, it could be a good moment to scan 28 healthcare AI stocks for other health focused technology names catching investors’ attention.

With the share price under pressure despite annual revenue of about US$11.7b and a recent annual net loss of roughly US$443 million, you have to ask: is Oscar Health now undervalued, or is the market already pricing in future growth?

Most Popular Narrative: 22% Undervalued

With Oscar Health last closing at $12.30 against a widely followed fair value estimate of about $15.78, the current price sits well below that narrative benchmark and puts the focus on what assumptions drive that gap.

Oscar Health's strong year over year revenue growth (29% in Q2) and consistently rising membership (28% growth, topping 2 million members) demonstrate competitive strength and sustained market demand, supporting top line revenue expansion.

Curious what kind of revenue trajectory and margin shift sit behind that fair value, and how a richer future earnings multiple fits in, given current losses and policy uncertainty? The full narrative lays out the exact earnings path and valuation math that connects today’s share price to that higher figure.

Result: Fair Value of $15.78 (UNDERVALUED)

However, there is still meaningful risk that higher claims costs in the ACA market and potential policy shifts around subsidies could pressure future margins and earnings.

Next Steps

Given the mix of optimism and concern running through this story, it makes sense to check the underlying data yourself and move quickly to form your own view. You can start with 2 key rewards and 1 important warning sign.

Looking for more investment ideas?

If this Oscar Health update has sharpened your focus, do not stop here. Use the same data driven lens to hunt for ideas that truly fit your portfolio.

• Target value first by checking 51 high quality undervalued stocks that pair fundamentals with prices that may not fully reflect their underlying strength.
• Prioritize resilience with 78 resilient stocks with low risk scores if you want companies that score well on stability and risk controls.
• Seek out fresh opportunities through our screener containing 23 high quality undiscovered gems before they sit firmly on everyone else’s watchlist.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.